Health Trials

Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis

ConditionsIn-stent Restenosis LesionCoronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChina National Center for Cardiovascular Diseases

About this trial

This study aims to evaluate, through a multicenter, prospective, double-blind, randomized, placebo-controlled clinical trial, whether immunosuppressive therapy improves target lesion-related cardiovascular outcomes compared to placebo treatment in patients with Rapid rEcurrence of Coronary Unexplained in-stent Restenosis (RECUR).

Eligibility criteria

Qualifiers

Age ≥ 18 years old

Able to understand the trial design and sign an informed consent form

Patients meeting the RECUR definition

Satisfactory results from revascularization within the past two weeks

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Immunosuppressive therapy
  • Placebo

Treatment groups

52 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

China National Center for Cardiovascular Diseases

Lead sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Collaborator

The First Hospital of Jilin University

Collaborator

Source ClinicalTrials.gov